Form 4: CareDx CFO Nathan Smith Granted 42,000 RSUs

CareDx, Inc. Chief Financial Officer Nathan Smith was granted 42,000 restricted stock units (RSUs) on August 7, 2025.

Summary

• Nathan Smith, Chief Financial Officer of CareDx, Inc. (CDNA), was granted 42,000 restricted stock units (RSUs).
• The transaction date for this grant was August 7, 2025.
• Each RSU represents a contingent right to receive one share of CareDx Common Stock upon settlement for no consideration.
• The vesting schedule dictates that 25% of the RSUs will vest on August 7, 2026, with the remaining 75% vesting in quarterly installments (1/16th of total) thereafter until fully vested, contingent on continued service.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of RSUs to a key executive like the CFO is a standard practice for retention and aligning interests with shareholders, indicating stability in management compensation structure. It's not a major market moving event but a positive signal for executive alignment.

Positives

• The grant of 42,000 restricted stock units (RSUs) to the Chief Financial Officer aligns his interests with long-term shareholder value.
• The vesting schedule, extending through quarterly installments, incentivizes the CFO's continued service and retention.

Negatives

• No explicit negative information is typically disclosed in a Form 4 filing, which reports a specific transaction.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The vesting schedule for the restricted stock units (RSUs) indicates an expectation of continued service from the Chief Financial Officer through at least August 7, 2026, and subsequent quarterly periods until full vesting.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across all industries for executive compensation and retention. It does not provide information related to broader industry trends or competitive dynamics within the healthcare or diagnostics sector.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of equity compensation is a standard practice for executive remuneration across various industries, including biotechnology and diagnostics.
• The vesting schedule, with an initial cliff vesting followed by quarterly installments, is a common structure designed to promote long-term executive retention and align interests with shareholder value, consistent with practices observed in companies like Illumina or Exact Sciences for similar executive roles.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution over time as RSUs vest into common stock, but also improved alignment of executive interests with long-term shareholder value.
• Employees: May signal stability in executive compensation practices.
• Management: The Chief Financial Officer receives significant equity compensation, incentivizing long-term performance and retention.

Next Steps

• Vesting of 25% of the RSUs on August 7, 2026.
• Subsequent quarterly vesting of 1/16th of the total RSUs until fully vested.

Key Dates

Keywords

CareDx, CDNA, Form 4, Restricted Stock Units, RSU, Insider Transaction, Nathan Smith, Chief Financial Officer, Equity Compensation, SEC Filing